Entropy Neurodynamics Reports Groundbreaking Phase 2 Data for Precision IV Psilocin in Binge Eating Disorder

First-Ever Clinical Validation of Precision-Controlled Intravenous Psilocin Platform

Entropy Neurodynamics has reached a pivotal clinical milestone by delivering the world’s inaugural clinical efficacy data for a precision-controlled intravenous psilocin platform. Results from Cohort 1 of the Phase 2 TRP-8803 trial in treatment-resistant Binge Eating Disorder confirm that the company’s proprietary delivery system enables rapid, predictable, and highly controlled therapeutic effects, yielding significant improvements across multiple psychiatric outcomes. This marks the first formal clinical trial evaluation of a precision-controlled IV psilocin formulation, providing crucial proof-of-concept for the TRP-8803 technology.

This clinical validation underscores the differentiation of the IV delivery platform compared to traditional oral psychedelic treatments. TRP-8803 demonstrated consistent rapid onset, predictable treatment intensity, and controlled offset in all Cohort 1 participants, indicating a mechanistically distinct approach to precision psychedelic therapy. Such differentiation is vital for the company’s long-term commercial ambitions, supporting TRP-8803’s potential as a scalable therapeutic platform across diverse psychiatric and gastrointestinal disorders where predictable rapid treatment effects are clinically advantageous.

50% Clinical Remission and Robust Secondary Endpoint Improvements in Binge Eating Disorder

Cohort 1 outcomes revealed strong efficacy across all endpoints in treatment-resistant Binge Eating Disorder patients. The primary endpoint was met with 50% of patients achieving complete clinical remission, defined as zero binge eating episodes in the four weeks post-treatment. Notably, 100% of patients experienced clinically meaningful improvements, surpassing predefined efficacy thresholds and demonstrating uniform response across the cohort. These headline results provide early and robust validation of TRP-8803’s therapeutic promise, significantly reducing development risk.

Secondary efficacy assessments showed substantial gains across psychiatric and behavioral metrics: a 74% average reduction in weekly binge episodes, 58% decrease in binge severity, 58% reduction in anxiety symptoms (GAD-7), 57% reduction in depression symptoms (PHQ-9), 63% improvement in overall life satisfaction, and a 33% improvement on the Clinical Global Impression scale. These multidimensional benefits suggest TRP-8803 may act as a broad-spectrum psychiatric therapeutic, enhancing its commercial appeal beyond addressing binge eating alone.

DSMB Endorses Progression to Cohort 2 Without Protocol Amendments

The Independent Data Safety Monitoring Board completed its thorough review of Cohort 1 safety data during the quarter, recommending advancement to Cohort 2 without any protocol modifications. This represents a significant risk mitigation milestone, confirming the original 60-minute infusion regimen remains appropriate and no safety concerns necessitate study design changes. The DSMB highlighted that Cohort 1 was well tolerated with predictable infusion characteristics and no safety flags, providing regulatory-grade evidence supporting the IV psilocin platform's safety.

Progression to Cohort 2 marks a critical juncture in the clinical development program. Recruitment for Cohort 2 is complete, with dosing initiated post-quarter. Topline data from Cohort 2 is expected in Q4 2026, positioning the company to deliver additional clinical evidence promptly, potentially accelerating regulatory discussions and partnership opportunities later in 2026. The smooth transition and safety profile reinforce confidence in trial execution and patient safety oversight.

Breakthrough Phase 2a IBS Data Validates Gut-Brain Axis Mechanism and Expands Market Potential

In addition to its lead Binge Eating Disorder indication, Entropy Neurodynamics announced breakthrough Phase 2a efficacy data in treatment-resistant Irritable Bowel Syndrome (IBS) at Digestive Disease Week (DDW) 2026. Data presented by researchers from Massachusetts General Hospital and Columbia University showed a 75% clinically meaningful response rate in treatment-resistant IBS patients. This validates the gut-brain axis mechanism central to the company’s broader strategy, indicating that precision-controlled IV psilocin may target pathophysiology beyond traditional psychiatric disorders linked to psychedelic therapy.

The IBS findings significantly bolster the commercial rationale for advancing TRP-8803 across multiple indications. Binge Eating Disorder and IBS represent distinct patient populations with different care pathways and unmet needs, suggesting a larger addressable market for the TRP-8803 platform than a single-indication approach. Validating the gut-brain mechanism offers mechanistic insight into how IV psilocin delivers therapeutic effects across clinically diverse conditions sharing neurobiological pathways. This multi-indication validation enhances the company’s strategic position for partnerships as pharmaceutical companies increasingly value therapies effective across related disease areas.

US Provisional Patent Filing Strengthens Intellectual Property for IBS Application

During the quarter, Entropy Neurodynamics filed a US provisional patent application covering TRP-8803’s use in Irritable Bowel Syndrome. This IP filing is strategically vital for securing long-term commercial exclusivity and reinforcing the company’s competitive stance in precision-controlled psychedelic therapies. The filing reflects a proactive approach to building a robust IP estate as clinical data accumulates across multiple indications. US patent protection for specific therapeutic uses can extend market exclusivity beyond compound patents, enabling separate protection periods for distinct disease applications.

This IP strategy underscores the company’s confidence in TRP-8803’s broad applicability and multi-indication commercial ambitions. By securing patents for particular disease uses alongside the core delivery technology, Entropy Neurodynamics is layering intellectual property defenses that may prove advantageous in licensing, partnerships, or commercialization. Management emphasized that expanding the IP portfolio supports regulatory engagement and strategic collaborations, indicating IP growth is a deliberate part of the development and commercialization strategy rather than solely defensive.

Strong Cash Position of $8.2 Million Supports Near-Term Clinical Activities

As of 30 June 2026, Entropy Neurodynamics reported $8.2 million in combined cash and funding facilities. While the company did not specify the split between cash on hand and committed facilities or provide cash runway guidance, this funding level offers financial flexibility to advance its clinical pipeline in the near to medium term. The completion of the capital-intensive Cohort 1 dosing and Cohort 2 recruitment with dosing underway post-quarter reduces immediate capital demands.

The sufficiency of this funding depends on factors not disclosed, including Cohort 2 trial size, per-patient costs, enrollment timelines for future studies, and overhead expenses. Clinical-stage biotech firms typically require additional capital raises to sustain development, and Entropy Neurodynamics may pursue equity, debt, or strategic partnerships as programs progress. No capital raising announcements were made in this update. Investors should be aware that future funding activities could impact shareholding and returns.

Broadened Development Focus Reflects Expanding Market Opportunities

Progress in Irritable Bowel Syndrome alongside Binge Eating Disorder highlights Entropy Neurodynamics’ strategic expansion beyond traditional psychiatric indications. Treatment-resistant IBS affects a large population with significant unmet needs due to inadequate symptom control by existing therapies. The 75% clinically meaningful response in Phase 2a IBS data suggests precision-controlled IV psilocin may target biological mechanisms not previously prioritized in psychedelic research, including modulation of the gut-brain axis and neuroinflammation.

This multi-indication approach offers strategic flexibility for partnerships and regulatory engagement. Demonstrating efficacy across multiple diseases enhances commercial potential and mitigates risks associated with single-indication development. Concurrent advancement of BED and IBS programs indicates the company’s capability to manage parallel clinical pathways, which may be critical if additional indications emerge. Management noted that expanding clinical evidence strengthens the basis for regulatory and partnership discussions, indicating a purposeful multi-indication strategy rather than opportunistic growth.

Regulatory Risk Mitigation and Accelerated Market Pathway Supported by Positive Phase 2 and Safety Data

The strong Cohort 1 efficacy results combined with the DSMB’s favorable safety review substantially reduce regulatory risks for TRP-8803. Demonstrating both efficacy and safety early is crucial given historical regulatory and patient concerns regarding psychedelic therapies. The well-tolerated profile and robust efficacy address major regulatory challenges and position the company advantageously for future regulatory interactions.

With Cohort 2 topline data expected in Q4 2026, Entropy Neurodynamics is positioned for potential regulatory progress in 2027, including discussions on Phase 3 trial design or expedited pathways. While no special designations were announced, breakthrough therapy status could accelerate timelines for treatment-resistant conditions with high unmet need. Investors should note that regulatory pathways for novel IV psilocin therapies remain evolving and timelines may vary.

Strategic Partnership and Licensing Prospects Expected as Clinical Data Advances

Management identified strategic partnerships as a key objective as clinical evidence grows. Positive results in BED and IBS enhance Entropy Neurodynamics’ appeal to pharmaceutical companies, contract research organizations, and healthcare investors. Larger pharma firms often seek to in-license precision psychedelic programs at Phase 2 to assess clinical and market potential prior to Phase 3 investment. The multi-indication profile of TRP-8803 may attract partners with diverse portfolios or those expanding psychedelic therapy capabilities.

Potential partnership structures include licensing deals, strategic investments, joint development, or acquisitions. Terms could affect shareholder value through upfront payments, milestones, royalties, or equity stakes. No partnership announcements have been made to date, and timing and terms remain uncertain. Investors should watch for future updates on corporate development, which could represent key inflection points in company valuation and shareholder returns. The company’s emphasis on partnerships indicates a strategic value creation approach rather than contingency planning.